ATE461213T1 - Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung - Google Patents

Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung

Info

Publication number
ATE461213T1
ATE461213T1 AT01952590T AT01952590T ATE461213T1 AT E461213 T1 ATE461213 T1 AT E461213T1 AT 01952590 T AT01952590 T AT 01952590T AT 01952590 T AT01952590 T AT 01952590T AT E461213 T1 ATE461213 T1 AT E461213T1
Authority
AT
Austria
Prior art keywords
fgf23
methods
growth factor
fibroblast growth
relates
Prior art date
Application number
AT01952590T
Other languages
German (de)
English (en)
Inventor
Michael Econs
Ken White
Tim Strom
Thomas Meitinger
Original Assignee
Advanced Res & Tech Inst
Univ Muenchen L Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461213(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advanced Res & Tech Inst, Univ Muenchen L Maximilians filed Critical Advanced Res & Tech Inst
Application granted granted Critical
Publication of ATE461213T1 publication Critical patent/ATE461213T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
AT01952590T 2000-07-19 2001-07-10 Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung ATE461213T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21913700P 2000-07-19 2000-07-19
PCT/US2001/021738 WO2002008271A1 (en) 2000-07-19 2001-07-10 Novel fibroblast growth factor (fgf23) and methods for use

Publications (1)

Publication Number Publication Date
ATE461213T1 true ATE461213T1 (de) 2010-04-15

Family

ID=22818027

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952590T ATE461213T1 (de) 2000-07-19 2001-07-10 Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung

Country Status (11)

Country Link
US (5) US7223563B2 (https=)
EP (2) EP2184296A1 (https=)
JP (2) JP2004504063A (https=)
KR (2) KR20090036151A (https=)
CN (1) CN1446227B (https=)
AT (1) ATE461213T1 (https=)
AU (2) AU7332301A (https=)
CA (1) CA2418215A1 (https=)
DE (1) DE60141582D1 (https=)
ES (1) ES2340662T3 (https=)
WO (1) WO2002008271A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
AU2001249125A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
KR100886276B1 (ko) * 2000-08-11 2009-03-04 기린 파마 가부시끼가이샤 인산 대사, 칼슘 대사, 석회화 및 비타민 ｄ 대사를조절하는 폴리펩티드 및 그것을 코딩하는 ｄｎａ
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
JPWO2002052009A1 (ja) * 2000-12-26 2004-04-30 中外製薬株式会社 血中リン濃度を低下させるヒトｆｇｆ２３タンパク質変異体
CA2443719A1 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
DE60329070D1 (de) * 2001-12-28 2009-10-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen den fibroblastenwachstumsfaktor 23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
WO2005045044A2 (en) * 2003-11-07 2005-05-19 Novartis Ag Use of fibroblast growth factor fragments
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
WO2005108607A1 (en) * 2004-05-09 2005-11-17 Technion Research & Development Foundation Ltd. Compositions and methods for treating disorders associated with abnormal phosphate metabolism
US20060236220A1 (en) * 2005-04-18 2006-10-19 Clearplay, Inc. Apparatus, System and Method for Associating One or More Filter Files with a Particular Multimedia Presentation
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
US8012694B2 (en) 2006-09-14 2011-09-06 Immutopics, Inc. Assay for the detection of phosphorylated PTH
US8058015B2 (en) 2007-01-22 2011-11-15 Medizinische Universität Innsbruck Markers for chronic kidney disease
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US20110183434A1 (en) * 2008-01-17 2011-07-28 Myles Wolf Diagnostic methods and kits using fibroblast growth factor-23
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CA2720888A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
US8889621B2 (en) * 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
KR101882533B1 (ko) 2010-08-31 2018-07-26 교와 메덱스 가부시키가이샤 섬유아세포 증식 인자-２３ 의 측정 방법 및 측정 시약
WO2012055096A1 (zh) * 2010-10-27 2012-05-03 温州医学院生物与天然药物开发中心有限公司 抗fgf-23抗体的制备方法及用途
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
US10745668B2 (en) * 2013-09-20 2020-08-18 Lonza Ltd Methods for nuclear reprogramming of cells
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
AU2015237176A1 (en) 2014-03-28 2016-10-20 New York University FGF23 fusion proteins
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
PE20170248A1 (es) * 2014-06-09 2017-04-14 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CN107810201A (zh) 2014-12-04 2018-03-16 诺华股份有限公司 使用klotho变体多肽的方法和组合物
CN105699664A (zh) * 2015-04-13 2016-06-22 陈柏龄 Fgf23检测试剂盒及其制备方法
EP3313996A1 (en) * 2015-06-25 2018-05-02 Amyris, Inc. Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CA3058306A1 (en) * 2017-03-28 2018-10-04 Ajinomoto Co., Inc. Additive for undifferentiation maintaining medium
WO2018221544A1 (ja) 2017-05-31 2018-12-06 協和メデックス株式会社 線維芽細胞増殖因子－２３の測定方法、測定試薬及び測定キット
WO2020047475A1 (en) * 2018-08-30 2020-03-05 The Uab Research Foundation Drug screening for fgf23-fgfr4 inhibitors
KR20220029546A (ko) * 2019-03-29 2022-03-08 아타르가, 엘엘씨 항 fgf23 항체
BR112021020888A2 (pt) * 2019-04-19 2021-12-21 Genethon Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
ATE478145T1 (de) 1999-06-02 2010-09-15 Genentech Inc Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
EP1672070A3 (en) * 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001042451A2 (en) 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
WO2001049740A1 (en) 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12
WO2001060850A1 (en) 2000-02-14 2001-08-23 Smithkline Beecham Corporation Novel compounds
CA2398603A1 (en) * 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
WO2002076467A1 (en) * 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism

Also Published As

Publication number Publication date
US7745406B2 (en) 2010-06-29
CN1446227B (zh) 2011-10-05
US7947810B2 (en) 2011-05-24
DE60141582D1 (de) 2010-04-29
CN1446227A (zh) 2003-10-01
EP2184296A1 (en) 2010-05-12
JP2008194039A (ja) 2008-08-28
ES2340662T3 (es) 2010-06-08
EP1303536B1 (en) 2010-03-17
CA2418215A1 (en) 2002-01-31
US20080241946A1 (en) 2008-10-02
KR20030029111A (ko) 2003-04-11
AU2001273323B2 (en) 2005-11-10
US7223563B2 (en) 2007-05-29
US8586317B2 (en) 2013-11-19
WO2002008271A1 (en) 2002-01-31
US20030181379A1 (en) 2003-09-25
US20120064544A1 (en) 2012-03-15
US20020156001A1 (en) 2002-10-24
AU7332301A (en) 2002-02-05
JP2004504063A (ja) 2004-02-12
EP1303536A1 (en) 2003-04-23
US20090311792A1 (en) 2009-12-17
KR20090036151A (ko) 2009-04-13
KR100924183B1 (ko) 2009-10-28
US7314618B2 (en) 2008-01-01
EP1303536A4 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
DE60141582D1 (de) Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
WO2001066595A3 (en) Human fgf-23 gene and gene expression products
DK1218509T3 (da) Fibroblast vækstfaktorlignende polypeptider
PT1232264E (pt) Gene fgf-21 humano e produtos da expressão do gene
ATE269102T1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
Armstrong et al. House-yard burials of enslaved laborers in eighteenth-century Jamaica
LV10308A (lv) Ciliarais neirotropais faktors
WO2001066596A3 (en) Human fgf-23 gene and gene expression products
ATE295734T1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
EP1451578A4 (en) ANGIOPOETINARY PROTEIN 3 ANGPTL3 CONTAINING COMPOSITION AND METHOD FOR ITS USE
DE69831609D1 (de) Pharmazeutische zusammensetzung zur stimulierung des wachstums von gram-positiven bazillen und zur erhöhung der azidität der vagina und ihre verwendung
ATE466106T1 (de) Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen
ATE469217T1 (de) Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
BR0116507A (pt) Fatores do crescimento de fibroblastos
EE200100472A (et) Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
DE69838509D1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
ATE169343T1 (de) Gemeinschaftlich verwendete genetische marker zur diagnostik der alzheimerschen krankheit, methode und diagnostischer reagenziensatz
DE69903278D1 (de) Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
EP1009768A4 (en) PERSEPHIN AND ASSOCIATED GROWTH FACTORS
DE60123109D1 (de) Mit schizophrenie in zusammenhang stehendes gen, das für ein potential-abhängiges ionkanal kodiert
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
DE60224778D1 (de) Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties